Eileen Barry

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model
    Eileen M Barry
    Center for Vaccine Development, University of Maryland, Baltimore, 685 West Baltimore Street, MD 21201, USA
    Vaccine 24:3727-34. 2006
  2. pmc Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit
    Tao Wu
    University of Maryland School of Medicine, Baltimore, MD, USA
    Infect Immun 79:4912-22. 2011
  3. pmc Vaccines against tularemia
    Eileen M Barry
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, USA
    Hum Vaccin 5:832-8. 2009
  4. pmc Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways
    Leah E Cole
    Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    J Immunol 180:6885-91. 2008
  5. pmc Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling
    Leah E Cole
    Department of Microbiology and Immunology, University of Maryland, Baltimore, Baltimore, MD 21201, USA
    J Leukoc Biol 87:275-81. 2010
  6. pmc Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages
    Leah E Cole
    Department of Microbiology and Immunology, University of Maryland, Baltimore, 660 West Redwood Street, Room 324, Baltimore, MD 21201, USA
    Infect Immun 75:4127-37. 2007
  7. ncbi request reprint Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208
    Karen L Kotloff
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 190:1745-54. 2004
  8. pmc Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Rev Microbiol 5:540-53. 2007
  9. ncbi request reprint Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media
    Karen L Kotloff
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Hum Vaccin 3:268-75. 2007
  10. ncbi request reprint Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy
    Christofer J Vindurampulle
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 22:3744-50. 2004

Research Grants

  1. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2004
  2. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2005
  3. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2006
  4. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2006
  5. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2007
  6. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2007
  7. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2009

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model
    Eileen M Barry
    Center for Vaccine Development, University of Maryland, Baltimore, 685 West Baltimore Street, MD 21201, USA
    Vaccine 24:3727-34. 2006
    ..These studies demonstrate the potential of the use of mixtures of live Shigella derivatives expressing ETEC antigens to serve as an immunogenic multivalent vaccine...
  2. pmc Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit
    Tao Wu
    University of Maryland School of Medicine, Baltimore, MD, USA
    Infect Immun 79:4912-22. 2011
    ..These candidates demonstrate the potential for a live attenuated vaccine to protect against disease caused by S. dysenteriae 1 and potentially to protect against the toxic effects of other Shiga toxin 1-expressing pathogens...
  3. pmc Vaccines against tularemia
    Eileen M Barry
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, USA
    Hum Vaccin 5:832-8. 2009
    ..This information has fostered the development of various vaccine candidates including acellular subunit, killed whole cell and live attenuated. This review summarizes the progress and promise of these various candidates...
  4. pmc Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways
    Leah E Cole
    Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    J Immunol 180:6885-91. 2008
    ....
  5. pmc Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling
    Leah E Cole
    Department of Microbiology and Immunology, University of Maryland, Baltimore, Baltimore, MD 21201, USA
    J Leukoc Biol 87:275-81. 2010
    ..Taken together, these data suggest that prolonging or enhancing the interaction between TLR2 and its agonist overcomes the "bridging" function ascribed previously to TIRAP...
  6. pmc Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages
    Leah E Cole
    Department of Microbiology and Immunology, University of Maryland, Baltimore, 660 West Redwood Street, Room 324, Baltimore, MD 21201, USA
    Infect Immun 75:4127-37. 2007
    ..Collectively, these data indicate that the primary macrophage response to F. tularensis LVS is overwhelmingly TLR2 dependent, requires de novo bacterial protein synthesis, and is independent of intracellular F. tularensis replication...
  7. ncbi request reprint Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208
    Karen L Kotloff
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 190:1745-54. 2004
    ....
  8. pmc Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Nat Rev Microbiol 5:540-53. 2007
    ....
  9. ncbi request reprint Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media
    Karen L Kotloff
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Hum Vaccin 3:268-75. 2007
    ....
  10. ncbi request reprint Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy
    Christofer J Vindurampulle
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 22:3744-50. 2004
    ..An ability to stimulate enhanced, accelerated responses to parenteral vaccination following mucosal priming may be advantageous in the immunoprophylaxis of many infectious diseases, including those of biodefense importance...
  11. pmc Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
    J Virol 77:5209-17. 2003
    ..flexneri can deliver measles DNA vaccines mucosally in cotton rats, inducing measles immune responses (including neutralizing antibodies) and protection, boosting strategies can now be evaluated in animals primed with MV DNA vaccines...
  12. pmc Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain
    Zeev Altboum
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 71:1352-60. 2003
    ..These findings pave the way for CS4 to be included in multivalent ETEC vaccines, including an attenuated Shigella live-vector-based ETEC vaccine...
  13. ncbi request reprint Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains
    Eileen M Barry
    Center for Vaccine Development, University of Maryland, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Vaccine 21:333-40. 2003
    ..Following mucosal immunization of guinea pigs with a mixed inoculum containing five Shigella strains each expressing a different ETEC antigen, immune responses were observed against each ETEC antigen plus the Shigella vector...
  14. pmc Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins
    Man Ki Song
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, 21201, USA
    J Virol 79:9854-61. 2005
    ..These data will help guide the design of DNA-based MV vaccines to be used early in life in a heterologous prime-boost strategy...
  15. doi request reprint Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen
    Karina Ramirez
    Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Hum Gene Ther 19:522-31. 2008
    ..Both vaccines were shown to be well tolerated and suitable for clinical trials and they are currently being tested in phase 1 studies in young adults...

Research Grants8

  1. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2004
    ..Typhi live vector strains, and provide preclinical data necessary for advancing promising candidates into clinical trials. ..
  2. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2005
    ..Typhi live vector strains, and provide preclinical data necessary for advancing promising candidates into clinical trials. ..
  3. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2006
    ..Typhi live vector strains, and provide preclinical data necessary for advancing promising candidates into clinical trials. ..
  4. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2006
    ....
  5. Conserved pneumococcal protein live-vector vaccine
    Eileen Barry; Fiscal Year: 2007
    ..Typhi live vector strains, and provide preclinical data necessary for advancing promising candidates into clinical trials. ..
  6. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2007
    ....
  7. Shigella dysenteriae vaccine construction
    Eileen Barry; Fiscal Year: 2009
    ....